ERBB2 and neoplasm: Upon comparison of the ATOX1 levels for different subtypes of disease, we found the highest prevalence of high cytoplasmatic ATOX1 levels in the tumor tissue of patients with HER2 subtype of disease (nhigh = 16 out of 16 (100%)) followed by Luminal (nhigh = 16 out of 18 (88%)) and TNBC subtypes (nhigh = 17 out of 23 (74%)), and we found a similar prevalence of high nuclear ATOX1 levels in the tumor tissue from patients with Luminal, HER2 and TNBC subtypes of disease (nhigh = 12 out of 18 (67%), nhigh = 4 out of 6 (67%) and nhigh = 15 out of 23 (65%), respectively) (Figure 3A,B).